UPDATE: MLV & Co. Upgrades Starwood Hotels & Resorts Worldwide
UPDATE: MLV Downgrades LaSalle Hotel Properties
UPDATE: MLV Initiates Pluristem Therapeutics at Buy on Unique Cell Therapy Platform
UPDATE: MLV Downgrades CapLease to Hold, Raises PT Following American Realty Capital Properties Merger Announcement
MLV Recent News
UPDATE: MLV Initiates Starwood Property Trust at Buy with $25.50 on Balance Sheet Strength
UPDATE: MLV Initiates NorthStar Realty Finance at Buy with PT of $6.50 on Valuation
UPDATE: MLV Initiates Buy, $6 PT on Resource Capital Corporation on Return Profile
UPDATE: MLV Initiates Cytokinetics with Buy, $4 PT
MLV Starts Coverage on Crimson Exploration, Gives Buy Rating and $5.50 PT
MLV Starts Coverage on Crimson Exploration, Gives Buy Rating and $5.50 PT
UPDATE: MLV Raises Transcept Pharmaceuticals' PT
UPDATE: MLV Raises Target to $10 on Curis
MLV Maintains Buy, $4 Target on Zalicus Post Settlement
MLV Reiterates Buy, $15 PT on Alnylam Pharmaceuticals
UPDATE: MLV Initiates Buy, $6 PT on Avanir Pharmaceutical
UPDATE: MLV Raises Price Target on Inhibitex to $26
UPDATE: MLV & Co Initiates Buy, $4 Target on Zalicus
UPDATE: MLV Raising Price Target on Cerus Corp.
UPDATE: MLV Raising Price Target on Inhibitex
MLV Maintains Buy on Double Eagle Petroleum
MLV Initiates Coverage of Sunesis Pharmaceuticals with a Buy Rating
MLV Initiates Coverage On Agenus
UPDATE: MLV Raises PT on Aastrom Biosciences to $7.50
MLV Maintains Buy on ArQule
UPDATE: MLV Reiterates Buy on Novavax, Reduces PT to $9.50
MLV Maintains Buy on Genomic Health
MLV Provides Color on Affymax